banner

Press Release

View printer-friendly version

<<  Back

ACADIA Pharmaceuticals Announces Pricing of Public Stock Offering

SAN DIEGO--(BUSINESS WIRE)--April 4, 2007--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced today the pricing of its public offering of 5,750,000 shares of its common stock. The public offering price of $15.50 per share will result in gross proceeds of $89.1 million and net proceeds, after underwriting commissions and other offering expenses, of $83.5 million to ACADIA. ACADIA also granted the underwriters a 30-day option to purchase up to 862,500 additional shares of its common stock, which could raise the net proceeds to ACADIA to $96.1 million, if exercised in full. All of the shares are being sold by ACADIA.

The book-running managers for the offering are Banc of America Securities LLC and Lehman Brothers Inc., the co-lead manager is Deutsche Bank Securities Inc., and the co-managers are Piper Jaffray & Co., JMP Securities LLC and Rodman & Renshaw, LLC.

A registration statement relating to these securities was filed and has been declared effective by the Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The offering of these securities may be made only by means of the prospectus supplement, related prospectus and any supplemental information relating to the offering. You may obtain copies of the prospectus supplement and related prospectus by contacting Banc of America Securities LLC, Capital Markets (Prospectus Fulfillment) by e-mail to dg.prospectus_distribution@bofasecurities.com or by mail to Banc of America Securities LLC, Capital Markets Operations, 100 West 33rd Street, 3rd Floor, New York, NY 10001 and Lehman Brothers Inc. by e-mail to qiana.smith@broadridge.com or by fax to (631) 254-7268 or by mail to Lehman Brothers, c/o Qiana Smith, Broadridge, Prospectus Fulfillment, 1155 Long Island Avenue, Edgewood, NY 11717.

ACADIA Pharmaceuticals is a biopharmaceutical company with its corporate headquarters located in San Diego, California and research and development operations in both San Diego and Malmo, Sweden.

CONTACT: ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director, Investor Relations
Thomas H. Aasen
Vice President and Chief Financial Officer
858-558-2871